Group 1 - The core point of the article is that Chengda Pharmaceutical (301201) announced a plan for a significant share reduction by its shareholder Qianhai Shengtai Investment Enterprise (Limited Partnership) [1] - Qianhai Shengtai holds 11,006,900 shares, accounting for 7.27% of the company's total share capital after excluding repurchased shares [1] - The shareholder plans to reduce its holdings by up to 11,006,970 shares within three months after the announcement date, using centralized bidding or block trading methods [1]

Core Viewpoint - Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its shareholding in Chengda Pharmaceutical by up to 11,006,897 shares, representing 7.27% of the company's total share capital after excluding repurchased shares, within a three-month period starting from September 29, 2025 [1][2]. Shareholder Information - Shenzhen Qianhai Shengtai holds 11,006,897 shares, accounting for 7.27% of the total share capital, and the total share capital of the company is 154,713,824 shares, with 151,469,124 shares after excluding repurchased shares [2]. - The reduction is due to the shareholder's operational needs, and the shares were acquired prior to the company's initial public offering and through capital reserve conversion [2]. Reduction Plan Details - The reduction will occur through centralized bidding or block trading, with a planned period from September 29, 2025, to December 28, 2025 [1][2]. - The reduction price will be determined based on market conditions, and adjustments will be made if there are changes in share capital during the reduction period [2]. Shareholder Commitment - The shareholder has provided commitments regarding the lock-up of shares and intentions for reduction, with no reductions made during the lock-up period [3].

Group 1 - The core point of the article is that Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), a shareholder holding 11,006,900 shares (7.27% of the total share capital after excluding repurchased shares) of Chengda Pharmaceutical (301201.SZ), plans to reduce its holdings within a specified timeframe [1] Group 2 - The planned reduction of shares will occur through centralized bidding or block trading methods [1] - The reduction period is set from September 29, 2025, to December 28, 2025 [1] - The maximum number of shares to be reduced is also 11,006,900, maintaining the same percentage of 7.27% of the total share capital after excluding repurchased shares [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201) announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its stake by up to 11,006,900 shares, which represents 7.11% of the company's total share capital, within three months after 15 trading days [1] Group 2 - The reduction will be executed through centralized bidding or block trading methods [1] - The announcement was made on the evening of September 5 [1] - The shareholder currently holds a 7.11% stake in the company [1]

Group 1 - The core point of the article is that Chengda Pharmaceutical (301201.SZ) announced that its shareholder, Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership), plans to reduce its holdings by up to 11,006,900 shares within three months after 15 trading days from the announcement date, which represents 7.27% of the total share capital excluding repurchased shares [1]

Core Viewpoint - Chengda Pharmaceutical (301201) announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings of 11.0069 million shares, representing 7.27% of the company's total share capital after excluding repurchased shares, within three months from September 29, 2025, to December 28, 2025, through centralized bidding or block trading [1] Summary by Relevant Sections - Shareholder Reduction Plan - Shenzhen Qianhai Shengtai Investment Enterprise intends to reduce its stake by up to 11.0069 million shares [1] - This reduction accounts for 7.27% of the company's total share capital after excluding repurchased shares [1] - The planned reduction period is from September 29, 2025, to December 28, 2025 [1] - Trading Method - The shares will be sold through centralized bidding or block trading methods [1]

Group 1 - The major shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its stake in Chengda Pharmaceutical from September 29, 2025, to December 28, 2025 [1] - The planned reduction involves selling up to 11.0069 million shares, which represents 7.27% of the company's total share capital after excluding repurchased shares [1] - The selling price will be determined based on market conditions [1]

证券代码：301201 证券简称：诚达药业 公告编号：2025-033 诚达药业股份有限公司 关于持股 5%以上股东减持股份的预披露公告 持股 5%以上股东深圳前海晟泰投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有诚达药业股份有限公司（以下简称"公司"、"发行人"）股份 11,006,897 股（占本公司剔除回购专户股份数后总股本比例 7.27%）的股东深圳 前海晟泰投资企业（有限合伙）计划在本公告披露之日起 15 个交易日后的 3 个 月内（2025 年 9 月 29 日至 2025 年 12 月 28 日）以集中竞价或大宗交易方式减 持本公司股份不超过 11,006,897 股（占本公司剔除回购专户股份数后总股本比 例 7.27%）。 2、根据《上市公司创业投资基金股东减持股份的特别规定》及《深圳证券 交易所上市公司创业投资基金股东减持股份实施细则》中关于创业投资基金投资 符合条件的企业的相关规定，深圳前海晟泰投资企业（有限合伙）（以下简称"前 海晟泰"）满足相 ...

Key Insights - The article highlights the recent trends in capital markets, focusing on sectors such as hard technology, healthcare, and internet services, with significant funding activities reported in these areas [6][7]. Hard Technology - The embodied intelligence sector remains a major hotspot, with RuoYu Robotics successfully completing a new round of angel+ financing amounting to hundreds of millions of RMB, led by its founding shareholder, Dongfang Precision Group [7][16]. - The robotics infrastructure company MechaMand completed nearly 500 million RMB in new financing, with participation from various investment funds including Xiong'an Fund and Huachuang Capital [7][17]. - Source Intelligent, focusing on dexterous hand development, announced several million RMB in financing led by Qiancheng Capital [14]. Healthcare - AI-driven innovative pharmaceuticals are gaining traction, with Xinhua Biopharmaceutical completing a series A financing of several tens of millions of USD, led by Xingze Capital [7][26]. - Nanjing Mainoway Pharmaceuticals secured 100 million RMB in B round financing, led by IDG Capital [7][27]. - Other notable funding includes HanTong Medical's completion of several million RMB in Pre-A+ financing [25] and the strategic investment in Suzhou Yulu Qianxing Biotechnology [35]. Internet/Enterprise Services - AI companies are actively raising funds, with Lingmou Technology completing a new round of financing worth several tens of millions of USD, led by BlueRun Ventures [37]. - ZeroMou Intelligent announced several tens of millions of RMB in Pre-B round financing, led by Lion City Capital [39]. - Orange Vision completed a new round of financing worth several million RMB, led by Yuntian Capital [40].

Group 1 - Meikaman's recent financing round raised nearly 500 million yuan, with investments from various funds aimed at enhancing its embodied intelligence technology and expanding product lines [2] - The Suzhou Kuanyu Equity Investment Fund was established with a registered capital of approximately 22.43 billion yuan, focusing on private equity investments and asset management [3] - The Horgos Silk Road Rongtong Industrial Investment Fund was established with a capital contribution of 1 billion yuan, also focusing on private equity investments [4] Group 2 - Weijian Intelligent completed a Series B financing round exceeding 100 million yuan, with funds directed towards product development in advanced packaging technologies for the AI era [6] - Two venture capital funds initiated by Shenzhen's collective economy, focusing on AI and emerging industries, have a total scale of 3 billion yuan [7] - Tianjin Jiayu Equity Investment Fund was established with a capital of 4.5 billion yuan, involving several insurance companies [8] Group 3 - Dowsure, a cross-border e-commerce platform, completed a C1 financing round with strategic investment from HSBC, enhancing its funding solutions for sellers [9] - A QFLP fund with a scale of 30 million USD has settled in Nantong, focusing on investments in the domestic medical and pharmaceutical sectors [10] - Shibeikang completed a nearly 100 million yuan Series B financing round, with funds aimed at accelerating R&D and expanding laboratory capabilities [11] Group 4 - The Guoxin Venture Capital Fund was established with a capital of 10 billion yuan, focusing on early-stage investments in hard technology sectors [13] - Prologis received a 1.5 billion USD investment from the Abu Dhabi Investment Authority to support its growth in supply chain and new energy sectors [14] - The first seed fund in Henan, with a scale of 200 million yuan, aims to support early-stage tech enterprises and facilitate technology transfer [16][17]